CT:NRI Nuvo Pharmaceuticals Inc.

Nuvo Pharmaceuticals Inc., a healthcare company, provides prescription and non-prescription products for pain, allergy, and dermatology in the United States, Canada, Europe, and internationally. The company operates through three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial; Cambia, a nonsteroidal anti-inflammatory drug for the treatment of migraine; Resultz, a non-prescription product intended to kill head lice and remove their eggs from hair; and Suvexx/Treximet, a medicine for migraine. The company also provides Pennsaid, a topical pain product that is used to treat the signs and symptoms of osteoarthritis of the knee; Pennsaid 2%, a follow-on product to Pennsaid; Vimovo for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; Yosprala for secondary prevention of cardiovascular and cerebrovascular events; and Heated Lidocaine/Tetracaine (HLT) Patch, a topical patch applied prior to painful medical procedures, such as venous access, blood draws, needle injections and minor dermatologic surgical procedures. The company was formerly known as Nuvo Research Inc. and changed its name to Nuvo Pharmaceuticals Inc. in March 2016. Nuvo Pharmaceuticals Inc. was founded in 1983 and is headquartered in Mississauga, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol NRIFF.

37.44 CAD
As of 12/17/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Drug Manufacturers-Specialty &
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    Toronto Stock Exchange
Exchange country:   Canada
Market cap:   10,363,080 CAD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy